Fosun-backed Shanghai Henlius Biotech has priced shares at the bottom of its range to raise $410m in its initial public offering ahead of public trading next week.
Shanghai Henlius Biotech, a China-based biotechnology developer backed by conglomerate Fosun, will raise $410m in its initial public offering, Reuters reported yesterday, citing people familiar with the matter.
The company issued approximately 64.7 million shares priced at HK$49.60 ($6.34) and will begin trading on the Hong Stock Exchange on September 25. The share price represents the bottom of Henlius’ range, set last week with a top end of $7.40.
Zhejiang Staidson Investment, the corporate venturing arm of pharmaceutical company…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
